Tocilizumab binds to canine IL-6 receptor and elicits in-vitro inhibitory biological response
The binding of TCZ to canine IL-6R resulting in a biological response is a specific example of the new possibilities to harness humanized mAb for canine diseases. TCZ may not be a feasible treatment due to the binding affinity and the high concentrations needed. However, future studies should explore potential suitable human mAb for treating canine autoimmune diseases.
Authors
- Siu‐Lung Chan (ORCID: https://orcid.org/0000-0001-7564-3287)
- J. Ehrlich
- Qiuming Yu (ORCID: https://orcid.org/0000-0002-2401-4664)
- Yael Merbl (ORCID: https://orcid.org/0000-0003-1065-0691)
- Michael Byron (ORCID: https://orcid.org/0000-0001-9857-2119)
- Jesus M. Lopez Baltazar
Institutions
- Cornell University (US)
Publication Details
- Journal
- Frontiers in Veterinary Science
- Published
- 2025-09-03
- DOI
- https://doi.org/10.3389/fvets.2025.1645414
- Citations
- 1
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 1.36